Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Forma disavows any obligation to update the information contained in such press releases after the date of their issuance.

Dates	Description
Jun 14, 2021	Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
Jun 11, 2021	Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
May 20, 2021	Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
May 17, 2021	Forma Therapeutics to Participate in Upcoming Investor Conferences
May 14, 2021	Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 06, 2021	Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021
Mar 30, 2021	Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update
Mar 30, 2021	Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study
Mar 23, 2021	Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
Feb 17, 2021	Forma Therapeutics to Participate in Upcoming Investor Conferences

Press Releases & Events

Press Releases